Olivier de Beaumont
Chief Tech/Sci/R&D Officer en Stallergenes Greer, Inc. .
Perfil
Olivier de Beaumont is currently the Senior VP & Head-Global Clinical Development at Stallergenes Greer, Inc. He previously worked as the Senior Vice President-Global Medical Affairs at Stallergenes SA and as the Chief Medical Officer & Head-Regulatory Affairs at Valerio Therapeutics SA. Dr. de Beaumont holds an MBA degree from ESCP Europe.
Cargos activos de Olivier de Beaumont
Empresas | Cargo | Inicio |
---|---|---|
Stallergenes Greer, Inc.
Stallergenes Greer, Inc. Pharmaceuticals: MajorHealth Technology Part of Stallergenes Greer Ltd., Stallergenes Greer, Inc. specializes in the development and commercialization of allergy immunotherapy products for use in the diagnosis and treatment of allergies. The private company is based in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/01/2005 |
Antiguos cargos conocidos de Olivier de Beaumont.
Empresas | Cargo | Fin |
---|---|---|
VALERIO THERAPEUTICS | Chief Tech/Sci/R&D Officer | 01/09/2022 |
STALLERGENES | Corporate Officer/Principal | - |
Formación de Olivier de Beaumont.
ESCP Europe | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
VALERIO THERAPEUTICS | Health Technology |
Empresas privadas | 2 |
---|---|
Stallergenes SA
Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
Stallergenes Greer, Inc.
Stallergenes Greer, Inc. Pharmaceuticals: MajorHealth Technology Part of Stallergenes Greer Ltd., Stallergenes Greer, Inc. specializes in the development and commercialization of allergy immunotherapy products for use in the diagnosis and treatment of allergies. The private company is based in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Olivier de Beaumont